on Piramal Pharma Solutions
Piramal Pharma's Grangemouth Facility Secures Updated MHRA GMP Certifications
Piramal Pharma Solutions has announced that its Grangemouth, UK facility has received updated MHRA GMP certificates. These certificates cover activities in the Helix building, including its warehouse and labs. Granted after a compliance report and successful inspection, they are valid for three years.
The facility specializes in antibody-drug conjugate development and plays a pivotal role in the ADCelerate™ program. The updated certificates ensure the facility can continue to support drug development with precision and reliability.
The achievement is backed by a strong regulatory history and successful inspections by global health authorities like the USFDA and others. CEO Peter DeYoung highlights this as a commitment to quality, helping partners bring therapies to patients efficiently.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Piramal Pharma Solutions news